{"id":"W4388045801","doi":"10.1016/j.jtho.2023.09.463","title":"P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Osimertinib; Medicine; T790M; Adjuvant; Oncology; Internal medicine; Lung cancer; Epidermal growth factor receptor; non-small cell lung cancer (NSCLC); Stage (stratigraphy); Cancer research; Cancer; Gefitinib; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001147858,0.001249472,0.001624846,0.0003103332,0.0003216784,0.001164234,0.0008137859,0.0008659583,0.002735066],"category_scores_gemma":[0.0004257758,0.0004811078,0.001156983,0.0002805858,0.0007869449,0.0007807264,0.0003141895,0.003139818,0.00100173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001001631,"about_ca_system_score_gemma":0.00174447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002230703,"about_ca_topic_score_gemma":0.008306652,"domain_scores_codex":[0.9997634,0.0000659844,0.000009159092,0.00004302923,0.00002411305,0.00009434998],"domain_scores_gemma":[0.999749,0.00003133459,0.00003329219,0.00001847978,0.00001275035,0.0001551628],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4210927,0.09663165,0.01305749,0.00194918,0.003176222,0.0008413752,0.000700139,0.01379368,0.1224289,0.001363513,0.01978443,0.3051808],"study_design_scores_gemma":[0.3941589,0.5525334,0.02873822,0.00009012313,0.001269061,0.0006129489,0.0002136688,0.00473428,0.009008516,0.0005580159,0.007998646,0.00008411847],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930139,0.001775259,0.0004103104,0.000463327,0.0001529437,0.0007855093,0.001103693,0.0001028808,0.002192129],"genre_scores_gemma":[0.9857836,0.002696051,0.001182088,0.0007717627,0.0001191707,0.0008605851,0.003147034,0.00005946301,0.005380309],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002735066,"threshold_uncertainty_score":0.00914973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0543660129831342,"score_gpt":0.4890541703410022,"score_spread":0.434688157357868,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}